Literature DB >> 12684923

Acquired T-helper 1 lymphocyte anergy following infection with Mycobacterium ulcerans.

Travis M Gooding1, Andrew S Kemp, Roy M Robins-Browne, May Smith, Paul D R Johnson.   

Abstract

We describe a patient with acquired T-helper lymphocyte anergy to mycobacteria following infection with Mycobacterium ulcerans. Before infection, the patient's peripheral blood mononuclear cells responded to in vitro stimulation with M. ulcerans by producing Th1 cytokines, but, after she developed an ulcer, the response was shifted toward production of Th2 cytokines. Immunomodulatory therapy may be an effective intervention for Buruli ulcer.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12684923     DOI： 10.1086/368315

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  23 in total

1.  Mycobacterium ulcerans triggers T-cell immunity followed by local and regional but not systemic immunosuppression.

Authors:  Alexandra G Fraga; Andrea Cruz; Teresa G Martins; Egídio Torrado; Margarida Saraiva; Daniela R Pereira; Wayne M Meyers; Françoise Portaels; Manuel T Silva; António G Castro; Jorge Pedrosa
Journal:  Infect Immun       Date:  2010-10-25       Impact factor: 3.441

2.  Use of the immunodominant 18-kiloDalton small heat shock protein as a serological marker for exposure to Mycobacterium ulcerans.

Authors:  Diana Diaz; Heinz Döbeli; Dorothy Yeboah-Manu; Ernestina Mensah-Quainoo; Arno Friedlein; Nicole Soder; Simona Rondini; Thomas Bodmer; Gerd Pluschke
Journal:  Clin Vaccine Immunol       Date:  2006-10-04

3.  Infection with Mycobacterium ulcerans induces persistent inflammatory responses in mice.

Authors:  Martinha S Oliveira; Alexandra G Fraga; Egídio Torrado; António G Castro; João P Pereira; Adhemar Longatto Filho; Fernanda Milanezi; Fernando C Schmitt; Wayne M Meyers; Françoise Portaels; Manuel T Silva; Jorge Pedrosa
Journal:  Infect Immun       Date:  2005-10       Impact factor: 3.441

4.  Cytokine responses to stimulation of whole blood from patients with Buruli ulcer disease in Ghana.

Authors:  B Daan Westenbrink; Ymkje Stienstra; Minke G Huitema; William A Thompson; Erasmus O Klutse; Edwin O Ampadu; H Marike Boezen; Piet C Limburg; Tjip S van der Werf
Journal:  Clin Diagn Lab Immunol       Date:  2005-01

Review 5.  Buruli ulcer: reductive evolution enhances pathogenicity of Mycobacterium ulcerans.

Authors:  Caroline Demangel; Timothy P Stinear; Stewart T Cole
Journal:  Nat Rev Microbiol       Date:  2009-01       Impact factor: 60.633

6.  Antioxidants protect keratinocytes against M. ulcerans mycolactone cytotoxicity.

Authors:  Alvar Grönberg; Louise Zettergren; Kerstin Bergh; Mona Ståhle; Johan Heilborn; Kristian Angeby; Pamela L Small; Hannah Akuffo; Sven Britton
Journal:  PLoS One       Date:  2010-11-04       Impact factor: 3.240

7.  The local immune response in ulcerative lesions of Buruli disease.

Authors:  A E Kiszewski; E Becerril; L D Aguilar; I T A Kader; W Myers; F Portaels; R Hernàndez Pando
Journal:  Clin Exp Immunol       Date:  2006-03       Impact factor: 4.330

8.  Mycolactone-mediated inhibition of tumor necrosis factor production by macrophages infected with Mycobacterium ulcerans has implications for the control of infection.

Authors:  Egídio Torrado; Sarojini Adusumilli; Alexandra G Fraga; Pamela L C Small; António G Castro; Jorge Pedrosa
Journal:  Infect Immun       Date:  2007-05-21       Impact factor: 3.441

9.  Systemic and local interferon-gamma production following Mycobacterium ulcerans infection.

Authors:  H S Schipper; B Rutgers; M G Huitema; S N Etuaful; B D Westenbrink; P C Limburg; W Timens; T S van der Werf
Journal:  Clin Exp Immunol       Date:  2007-09-27       Impact factor: 4.330

Review 10.  Buruli ulcer disease: prospects for a vaccine.

Authors:  Kris Huygen; Ohene Adjei; Dissou Affolabi; Gisela Bretzel; Caroline Demangel; Bernhard Fleischer; Roch Christian Johnson; Jorge Pedrosa; Delphin M Phanzu; Richard O Phillips; Gerd Pluschke; Vera Siegmund; Mahavir Singh; Tjip S van der Werf; Mark Wansbrough-Jones; Françoise Portaels
Journal:  Med Microbiol Immunol       Date:  2009-02-07       Impact factor: 3.402
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.